Click here to get full coverage on Biotech Larimar heads to Miami for back-to-back investor meetings in March - stocktitan.net

Biotech Larimar heads to Miami for back-to-back investor meetings in March  stocktitan.net

Biotech Larimar heads to Miami for back-to-back investor meetings in March - stocktitan.net

Click here to get full coverage on Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages  MarketBeat

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Click here to get full coverage on Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance

Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?  Yahoo Finance

Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - msn.com

Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13  msn.com

Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - msn.com

Click here to get full coverage on Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative

Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases  Quiver Quantitative

Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative

Click here to get full coverage on Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR - TipRanks

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR  TipRanks

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR - TipRanks

Click here to get full coverage on LRMR SEC Filings - Larimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net

LRMR SEC Filings - Larimar Therapeutics Inc 10-K, 10-Q, 8-K Forms  stocktitan.net

LRMR SEC Filings - Larimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net

Click here to get full coverage on LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView

LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment  TradingView

LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView

Click here to get full coverage on Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia - simplywall.st

Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia  simplywall.st

Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia - simplywall.st

Click here to get full coverage on Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday - MarketBeat

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday  MarketBeat

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday - MarketBeat

Click here to get full coverage on We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully - simplywall.st

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully  simplywall.st

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully - simplywall.st

Click here to get full coverage on FDA grants Breakthrough status to rare disease drug as June filing nears - stocktitan.net

FDA grants Breakthrough status to rare disease drug as June filing nears  stocktitan.net

FDA grants Breakthrough status to rare disease drug as June filing nears - stocktitan.net

Click here to get full coverage on Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat

Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)  MarketBeat

Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat

Click here to get full coverage on Rare-disease biotech Larimar seeks $75M to fund key drug - stocktitan.net

Rare-disease biotech Larimar seeks $75M to fund key drug  stocktitan.net

Rare-disease biotech Larimar seeks $75M to fund key drug - stocktitan.net

Click here to get full coverage on With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest  Yahoo Finance

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance

Click here to get full coverage on Rare-disease biotech Larimar raises $100M in stock sale - stocktitan.net

Rare-disease biotech Larimar raises $100M in stock sale  stocktitan.net

Rare-disease biotech Larimar raises $100M in stock sale - stocktitan.net

Click here to get full coverage on Insider Purchase: Director at $LRMR Buys 2,000,000 Shares | LRMR Stock News - Quiver Quantitative

Insider Purchase: Director at $LRMR Buys 2,000,000 Shares | LRMR Stock News  Quiver Quantitative

Insider Purchase: Director at $LRMR Buys 2,000,000 Shares | LRMR Stock News - Quiver Quantitative

Click here to get full coverage on Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - stocktitan.net

Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027  stocktitan.net

Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - stocktitan.net

Click here to get full coverage on Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp - simplywall.st

Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp  simplywall.st

Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp - simplywall.st

Click here to get full coverage on Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st

Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners  simplywall.st

Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st

Click here to get full coverage on FIRST LOOK: LeBron James' Buckets restaurant at House Three Thirty in Akron - WKYC

FIRST LOOK: LeBron James' Buckets restaurant at House Three Thirty in Akron  WKYC

FIRST LOOK: LeBron James' Buckets restaurant at House Three Thirty in Akron - WKYC

Click here to get full coverage on Larimar surges on FDA breakthrough status for lead asset - Seeking Alpha

Larimar surges on FDA breakthrough status for lead asset  Seeking Alpha

Larimar surges on FDA breakthrough status for lead asset - Seeking Alpha

Click here to get full coverage on Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR)  Seeking Alpha

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha

Click here to get full coverage on Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts  MarketBeat

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Click here to get full coverage on Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance

Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment?  Yahoo Finance

Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance

Click here to get full coverage on Larimar Therapeutics (Nasdaq: LRMR) targets Q2 2026 BLA; Phase 3 to adopt modified dosing - stocktitan.net

Larimar Therapeutics (Nasdaq: LRMR) targets Q2 2026 BLA; Phase 3 to adopt modified dosing  stocktitan.net

Larimar Therapeutics (Nasdaq: LRMR) targets Q2 2026 BLA; Phase 3 to adopt modified dosing - stocktitan.net

Click here to get full coverage on Larimar: Q4 Earnings Snapshot - KTVB

Larimar: Q4 Earnings Snapshot - KTVB

Click here to get full coverage on $LRMR stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

$LRMR stock is up 28% today. Here's what we see in our data.  Quiver Quantitative

$LRMR stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Experimental Friedreich’s ataxia drug gets FDA Breakthrough nod - stocktitan.net

Experimental Friedreich’s ataxia drug gets FDA Breakthrough nod  stocktitan.net

Experimental Friedreich’s ataxia drug gets FDA Breakthrough nod - stocktitan.net

Click here to get full coverage on Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - Yahoo Finance

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential  Yahoo Finance

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - Yahoo Finance

Click here to get full coverage on LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus

LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 |  GuruFocus

LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus

Click here to get full coverage on Latest LRMR News - Larimar Therapeutics Announces Completion o... - stocktitan.net

Latest LRMR News - Larimar Therapeutics Announces Completion o...  stocktitan.net

Latest LRMR News - Larimar Therapeutics Announces Completion o... - stocktitan.net

Click here to get full coverage on Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation - Benzinga

Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation  Benzinga

Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation - Benzinga

Click here to get full coverage on Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00 - MarketBeat

Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00  MarketBeat

Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00 - MarketBeat

Click here to get full coverage on Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative

Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each  Quiver Quantitative

Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative

Click here to get full coverage on Deerfield boosts Larimar Therapeutics (LRMR) stake to 34.41% of shares - stocktitan.net

Deerfield boosts Larimar Therapeutics (LRMR) stake to 34.41% of shares  stocktitan.net

Deerfield boosts Larimar Therapeutics (LRMR) stake to 34.41% of shares - stocktitan.net

Click here to get full coverage on LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Eastern Progress

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?  Eastern Progress

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Eastern Progress

Click here to get full coverage on Larimar Therapeutics jumps on FDA Breakthrough Therapy Designation for nomlabofusp - Quiver Quantitative

Larimar Therapeutics jumps on FDA Breakthrough Therapy Designation for nomlabofusp  Quiver Quantitative

Larimar Therapeutics jumps on FDA Breakthrough Therapy Designation for nomlabofusp - Quiver Quantitative

Click here to get full coverage on Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates - GuruFocus

Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates  GuruFocus

Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates - GuruFocus

Click here to get full coverage on LRMR Analyst Update: Citigroup Raises Price Target for Larimar T - GuruFocus

LRMR Analyst Update: Citigroup Raises Price Target for Larimar T  GuruFocus

LRMR Analyst Update: Citigroup Raises Price Target for Larimar T - GuruFocus

Click here to get full coverage on LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus

LRMR Stock Rating Maintained Outperform by Wedbush, Price Target  GuruFocus

LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus

Click here to get full coverage on LRMR Financials: Income Statement, Balance Sheet & Cash Flow - stocktitan.net

LRMR Financials: Income Statement, Balance Sheet & Cash Flow  stocktitan.net

LRMR Financials: Income Statement, Balance Sheet & Cash Flow - stocktitan.net

Click here to get full coverage on LRMR: Wedbush Reiterates Outperform Rating at $11 | LRMR Stock N - GuruFocus

LRMR: Wedbush Reiterates Outperform Rating at $11 | LRMR Stock N  GuruFocus

LRMR: Wedbush Reiterates Outperform Rating at $11 | LRMR Stock N - GuruFocus

Click here to get full coverage on Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha

Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow  Seeking Alpha

Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha

Click here to get full coverage on Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR - Business Wire

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR  Business Wire

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR - Business Wire

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire

Click here to get full coverage on Larimar Therapeutics (LRMR) Surges on FDA Breakthrough Designati - GuruFocus

Larimar Therapeutics (LRMR) Surges on FDA Breakthrough Designati  GuruFocus

Larimar Therapeutics (LRMR) Surges on FDA Breakthrough Designati - GuruFocus

Click here to get full coverage on Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2025 Financial Results  GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on LRMR Expands Offering to $100 Million - GuruFocus

LRMR Expands Offering to $100 Million  GuruFocus

LRMR Expands Offering to $100 Million - GuruFocus

Click here to get full coverage on Larimar Therapeutics wins FDA Breakthrough Therapy Designation for nomlabofusp; BLA on track for June 2026 - TradingView

Larimar Therapeutics wins FDA Breakthrough Therapy Designation for nomlabofusp; BLA on track for June 2026  TradingView

Larimar Therapeutics wins FDA Breakthrough Therapy Designation for nomlabofusp; BLA on track for June 2026 - TradingView

Click here to get full coverage on 100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - stocktitan.net

100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential  stocktitan.net

100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - stocktitan.net

Click here to get full coverage on Larimar Therapeutics stock falls 8% on upsized $100 million offering - Investing.com

Larimar Therapeutics stock falls 8% on upsized $100 million offering  Investing.com

Larimar Therapeutics stock falls 8% on upsized $100 million offering - Investing.com

Click here to get full coverage on LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25  富途牛牛

LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

Click here to get full coverage on Larimar’s Stock Soars After FDA Grants Breakthrough Therapy Designation - StocksToTrade

Larimar’s Stock Soars After FDA Grants Breakthrough Therapy Designation  StocksToTrade

Larimar’s Stock Soars After FDA Grants Breakthrough Therapy Designation - StocksToTrade

Click here to get full coverage on Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - GlobeNewswire

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering  GlobeNewswire

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering - GlobeNewswire

Click here to get full coverage on Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus

Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10  GuruFocus

Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus

Click here to get full coverage on Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView

Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised  TradingView

Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView

Click here to get full coverage on Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings - RTTNews

Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings  RTTNews

Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings - RTTNews

Click here to get full coverage on Laminar Therapeutics Stock Is Popping Today: What's Going On? - Benzinga

Laminar Therapeutics Stock Is Popping Today: What's Going On?  Benzinga

Laminar Therapeutics Stock Is Popping Today: What's Going On? - Benzinga

Click here to get full coverage on Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia - Quiver Quantitative

Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia  Quiver Quantitative

Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia - Quiver Quantitative

Click here to get full coverage on MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES - PR Newswire

MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES  PR Newswire

MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES - PR Newswire

Click here to get full coverage on Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com

Larimar Therapeutics: Deerfield entities buy $25m in stock  Investing.com

Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com

Click here to get full coverage on Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail

Larimar Advances Nomlabofusp Toward 2026 BLA Submission  The Globe and Mail

Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail

Click here to get full coverage on Larimar Therapeutics stock dips after pricing $100M share offering - msn.com

Larimar Therapeutics stock dips after pricing $100M share offering  msn.com

Larimar Therapeutics stock dips after pricing $100M share offering - msn.com

Click here to get full coverage on LRMR 8-K & SEC Filings - Yahoo Finance

LRMR 8-K & SEC Filings - Yahoo Finance

Click here to get full coverage on Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today?  Stocktwits

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits

Click here to get full coverage on Larimar Therapeutics Announces Pricing Of Upsized $100 Million Underwritten Public Offering - TradingView

Larimar Therapeutics Announces Pricing Of Upsized $100 Million Underwritten Public Offering  TradingView

LRMR

Price Chart

Key Statistics

Technicals

About LRMR

Latest News

Biotech Larimar heads to Miami for back-to-back investor meetings in March - stocktitan.net

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers